miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression

Open Access

Peer-reviewed

Research Article

Florian Kopp,

Affiliation Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
⨯
Prajakta S. Oak,

Affiliation Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
⨯
Ernst Wagner,

Affiliation Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
⨯
Andreas Roidl

* E-mail: andreas.roidl@cup.uni-muenchen.de

Affiliation Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
⨯

Reader Comments (0)

BT474 cells
Is the Subject Area "BT474 cells" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Transfection
Is the Subject Area "Transfection" applicable to this article?

Thanks for your feedback.
Molecular evolution
Is the Subject Area "Molecular evolution" applicable to this article?

Thanks for your feedback.
MicroRNAs
Is the Subject Area "MicroRNAs" applicable to this article?

Thanks for your feedback.
Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.
Cytotoxicity assay
Is the Subject Area "Cytotoxicity assay" applicable to this article?

Thanks for your feedback.